All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BX003
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BX003
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Results support the potential of a phage therapy approach for the treatment of both IBD and PSC, demonstrating the ability to identify and select phage with direct relevance to patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DUR-928
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
The additional biomarker data suggests that epigenetic modulation by DUR-928 is worthy of further study in NASH patients. DURECT's lead drug candidate, DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
The findings showed robust and sustained FXR activation, which Metacrine believes is key to optimizing therapeutic benefits. Combined with a favorable pharmacological and tolerability profile, the results support the therapeutic potential of MET409 for patients with NASH.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB1211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GB1211
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
GB1211 has been shown to be effective in several pre-clinical fibrosis models, without any signs of toxicity. Galectin-3 plays a key role in fibrosis development through cellular activation and production of collagen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EP547
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EP547
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sanofi Ventures
Deal Size: $77.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 14, 2020
Details:
Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings observed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AXA1125,AXA1957
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Poster presentation contains data demonstrating AXA1125’s multifactorial effects on markers of metabolism, inflammation and fibrosis in subjects with NAFLD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CB4211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CB4211
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2020
Details:
CohBar intends to use the net proceeds from the offering, together with its existing cash resources, for general corporate purposes, funding preclinical and clinical development of its peptides, increasing working capital, operating expenses and capital expenditures.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
